EDITORIAL Price of Protection — Microaxial Flow Pump in High-Risk PCI Brahmajee K. Nallamothu, Brett L. Wanamaker N Engl J Med 2026;394:1855-1856 DOI: 10.1056/NEJMe2602727 In the catheterization laboratory, the most consequential decisions are frequently not about whether to treat, but rather about how far to extend treatment. Nowhere is that tension more apparent than in high-risk percutaneous coronary intervention (PCI). In these cases, the margin between...

ORIGINAL ARTICLE A Phase 3 Trial of Brepocitinib in Dermatomyositis Ruth Ann Vleugels, Julie J. Paik, Iazsmin Bauer Ventura, et al N Engl J Med 2026;394:1883-1893 DOI: 10.1056/NEJMoa2503531 Abstract BACKGROUND Brepocitinib is a first-in-class, oral, selective TYK2–JAK1 inhibitor that blocks cytokine signaling, which has been implicated in dermatomyositis. METHODS In this phase 3, double-blind, randomized, place...

PERSPECTIVE Can AI Say “I Don’t Know”? Andrea Sikora, Leo A. Celi, Raja-Elie E. Abdulnour N Engl J Med 2026;394:1873-1875 DOI: 10.1056/NEJMp2517624 I will not be ashamed to say “I know not.” — Hippocratic Oath A first-year resident is asked, “What explains the patient’s rising creatinine?” She pauses. “I don’t know ….” The team reviews the patient’s medications and risk factors and chooses a cautious plan involving chec...

Vasoactive Medications and Microcirculation in Septic Shock In Sepsis Thu, 9 Apr 2026 A new review examines the effects of vasoactive medications on the microcirculation in septic shock to synthesise current knowledge and identify gaps in evidence. Sepsis remains a leading cause of inpatient mortality, with rates approaching 30%, and although management strategies focus on restoring macrohaemodynamic parameters such as mean arterial pressure (MAP) and ...

Invited Commentary  Exchange Transfusion for Severe Babesiosis—Insights From a Multicenter Retrospective Analysis Eric A. Meyerowitz, Johanna P. Daily JAMA Intern Med 2026;186;(5):607-608. doi:10.1001/jamainternmed.2026.0252 Babesia microti is a tickborne intraerythrocytic parasite reported in at least 24 states across the US, with 1827 cases reported in 2020.1 Rising cases have been attributed to climate and weather changes across the country. Severe bab...

ORIGINAL ARTICLE Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts Frederick G. Hayden, Masaharu Shinkai, Tristan W. Clark, et al N Engl J Med 2026;394:1905-1915 Abstract BACKGROUND Ensitrelvir, an oral inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease, is approved in Japan for the treatment of mild-to-moderate coronavirus disease 2019 (Covid-19). Previously...

Original Investigation  Surgery Surgeon Volume and Clinical Outcomes After Robotic Elective and Emergency General Surgery Natasha Houshmand, I-Fan Shih, Alistair J. Kent, et al JAMA Netw Open 2026;9;(5):e2611774. doi:10.1001/jamanetworkopen.2026.11774 Key Points Question  Is annual surgeon robotic case volume associated with outcomes for both elective and emergency robotic general surgery procedures? F...

Editorial  Dapagliflozin to Reduce the Risk of Perioperative Acute Kidney Injury in Elective Cardiac Surgery Wolfgang C. Winkelmayer, Glenn M. Chertow JAMA Published Online: July 30, 2026 doi: 10.1001/jama.2026.7477 Sodium-glucose cotransporter 2 (SGLT2) inhibitors have constituted a major advancement for the treatment of patients with chronic kidney disease and/or heart failure, with sizeable benefits in reducing progression of kidney disease and in r...

Editorial  The Price of Advice—Do Management Consultants Deliver Value to Nonprofit Hospitals? Thomas C. Buchmueller, Helen G. Levy JAMA Published Online: May 4, 2026 doi: 10.1001/jama.2026.4362 In a well-publicized case that stoked public outrage, Providence, a nonprofit health system headquartered in the state of Washington, implemented a program in 2018 called Rev Up to increase revenue collection from patients.1 Following enforcement action by the ...

Original Investigation  Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial Maartina J. P. Oosterom-Eijmael, Abraham H. Hulst, Nelson P. Monteiro de Oliveira, et al JAMA Published Online: July 30, 2026 doi: 10.1001/jama.2026.9268 Key Points Question  Among patients undergoing elective cardiac surgery, does dapagliflozin, initiated 1 day prior to surgery, reduce acute kidney injury at 7 days after su...